China SXT Pharmaceuticals
SXTC
1 hedge funds and large institutions have $131K invested in China SXT Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
293% more capital inflows, than outflows
Capital inflows: $2.05M | Capital outflows: $523K
8.88% more ownership
Funds ownership: 0.28% → 9.16% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$241K |
| 2 |
Invesco
Atlanta,
Georgia
|
-$137K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$85.9K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
-$36.4K |
| 5 |
Virtu Financial
New York
|
-$20K |
SXTC Hedge Fund Activity: Q1 2026 in Review
1 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q1 2026, worth a combined $131K — down 75% from $524K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SXTC positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.05M. The largest seller was Citadel Advisors, cutting an estimated $241K.
- 1 institutional investor held China SXT Pharmaceuticals (SXTC) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $131K of China SXT Pharmaceuticals stock for Q1 2026, down 75% quarter-over-quarter.
- 1 fund opened new China SXT Pharmaceuticals positions in Q1 2026 and 0 closed out, a net change of +1 holder.
- The largest China SXT Pharmaceuticals buyer in Q1 2026 was Sabby Management, an estimated $2.05M added.
- The largest China SXT Pharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $241K sold.
Based on aggregated 13F filings for Q1 2026.